Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)

    The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, USA, from May 31 to June 4. The ASCO Annual Meeting gathers oncology experts, doctors, and researchers from around the world to share the latest research findings, discuss cutting-edge diagnostic and therapeutic techniques, and advance the field of oncology. A study…

    2024.06.15
  • ASCO & EHA Special丨Professor Jun Zhu: Opportunities and Challenges for Chinese Original Anticancer Drugs on the International Stage

    As summer begins, the sun shines warmly and everything thrives. In this vibrant season, two major international events in the pharmaceutical world—the American Society of Clinical Oncology (ASCO 2024) and the European Hematology Association (EHA 2024) annual meetings—are about to take place. These meetings are not only platforms for showcasing global pharmaceutical innovations but also…

    2024.06.15
  • Professor Man Li:  From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special

    In this “Man Talks Breast Cancer: ASCO Special,” Professor Man Li’s team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in…

    2024.06.15
  • EASL Special New Voices丨Latest Advances in ACLF: Transition from ACLF to Pre-ACLF

    From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. This event brought together over 7,000 liver disease specialists from around the world. On the third day of the conference, “Hepatology Digest” invited Dr. Wenyi Gu, a protégé of Professors Jonel Trebicka from University…

    2024.06.15
  • EASL China Voice: Professor Liang Peng’s Team Reveals Key Mechanism of Pyroptosis in Hepatocytes Mediating ACLF Liver Injury

    From June 5 to 8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy. During the conference, Professor Liang Peng’s team from the Third Affiliated Hospital ,Sun Yat-sen University unveiled the significant link between hepatocyte pyroptosis and acute-on-chronic liver failure (ACLF). The research found that…

    2024.06.14
  • EASL2024 Interview | Dr. Terry Yip: Prognostic significance of a change in liver stiffness measurement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

    With the rapid development of modern medical technology, non-invasive assessment methods have attracted more and more attention. In the field of metabolically associated fatty liver disease (MAFLD), liver hardness measurement (LSM) has become an important indicator for non-invasive assessment of liver-related events. At the annual meeting of the European Association for the Study of the…

    2024.06.14
  • Professor Yongxian Hu: Advances in CD7 CAR-T Cell Therapy丨2024 Nanjing Lymphoma Forum

    With the continuous advancement of immunotherapy technologies, CD7 CAR-T cell therapy is emerging as a new option for treating leukemia and lymphoma, showing significant potential. Recent clinical studies have revealed multiple new developments in CD7 CAR-T cell therapy. However, challenges remain, such as improving safety, reducing side effects, and optimizing treatment protocols to enhance long-term…

    2024.06.14
  • ASCO International Perspectives丨Dr. Areej El-Jawahri: Collaborative Palliative Care Optimizes End-of-Life Strategies for AML and MDS Patients

    At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, a multicenter randomized clinical trial was presented, focusing on a collaborative palliative care and oncology model for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) receiving non-intensive treatment (Abstract LBA6508). Dr. Areej El-Jawahri from Massachusetts General Hospital shared her professional insights…

    2024.06.14
«previous next»
Recent Posts
  • 10th Yunling Breast Cancer Conference | Professor Yehui Shi: From “Targeting What Can Be Targeted” to Moving ADCs Forward — Reshaping the Precision Treatment Pathway for Advanced HR+/HER2− Breast Cancer
  • Director Ying Jiang: Optimizing the Combination of Transplantation and CAR-T Therapy to Explore New Pathways for Immunotherapy in Hematologic Malignancies | Gaobo Medical Forum 2026
  • Professor Ma Jun: Current Landscape and Future Perspectives of Cell Therapy Amid the CGT Wave | 2026 Cross-Strait Hematology Academic Conference
  • Professor Wei Xu: Differential Diagnosis of Lymphoproliferative Disorders丨2026 Cross-Strait Hematology Academic Conference
  • the 14th Lu Daopei Hematology Forum | Professor Yuqian Sun: Precision Assessment, Tailored Strategies — Current Status and Future Directions of Hematopoietic Stem Cell Transplantation in Older Patients
Recent Comments
    Archives
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top